NEOS Investment Management LLC Increases Stock Position in Stryker Corporation $SYK

NEOS Investment Management LLC increased its holdings in shares of Stryker Corporation (NYSE:SYK) by 12.4% during the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 55,637 shares of the medical technology company’s stock after purchasing an additional 6,146 shares during the period. NEOS Investment Management LLC’s holdings in Stryker were worth $17,517,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Sankala Group LLC bought a new stake in Stryker during the 4th quarter valued at $26,000. Godfrey Financial Associates Inc. bought a new position in shares of Stryker in the 4th quarter worth $26,000. United Financial Planning Group LLC purchased a new stake in shares of Stryker during the 3rd quarter worth $27,000. Atlas Capital Advisors Inc. purchased a new stake in shares of Stryker during the 4th quarter worth $27,000. Finally, Gables Capital Management Inc. bought a new stake in Stryker during the second quarter valued at about $25,000. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Stock Down 1.6%

SYK stock opened at $302.92 on Friday. The stock has a market capitalization of $116.19 billion, a PE ratio of 31.39, a price-to-earnings-growth ratio of 1.93 and a beta of 0.76. Stryker Corporation has a 52 week low of $281.00 and a 52 week high of $396.37. The company has a quick ratio of 1.33, a current ratio of 2.16 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average of $328.84 and a 200 day moving average of $329.73.

Stryker (NYSE:SYK) last issued its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 15.03 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio (DPR) is 36.48%.

Insider Buying and Selling

In other news, insider Dylan Crotty sold 441 shares of the company’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $328.61, for a total value of $144,917.01. Following the sale, the insider directly owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This represents a 6.74% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Debra King sold 826 shares of the company’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 351,267 shares of company stock worth $118,197,701 in the last 90 days. Insiders own 4.60% of the company’s stock.

Wall Street Analyst Weigh In

SYK has been the subject of a number of recent research reports. Leerink Partners reduced their target price on shares of Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday, June 5th. Evercore set a $350.00 price objective on shares of Stryker in a research report on Monday, July 6th. Truist Financial boosted their price objective on shares of Stryker from $330.00 to $340.00 and gave the stock a “hold” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. decreased their target price on shares of Stryker from $400.00 to $350.00 and set an “overweight” rating for the company in a research report on Friday, July 31st. Finally, UBS Group initiated coverage on shares of Stryker in a report on Tuesday, July 28th. They issued a “buy” rating and a $400.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Stryker Company Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.